

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/189,043	11/09/1998 -	SCOTT M. ROCKLAGE	238/117	5059	
21834	7590 - 07/28/2003				
BECK AND TYSVER 2900 THOMAS AVENUE SOUTH SUITE 100 MINNEAPOLIS, MN 55419		EXAMINER			
			HARTLEY, N	HARTLEY, MICHAEL G	
			ART UNIT	PAPER NUMBER	
			1616		
			DATE MAILED: 07/28/2003	24	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
,	09/189,043	ROCKLAGE ET AL.				
Office Action Summary	Examin r	Art Unit				
	Michael G. Hartley	1616				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be y within the statutory minimum of thirty (30) d vill apply and will expire SIX (6) MONTHS fro , cause the application to become ABANDON	timely filed ays will be considered timely. m the mailing date of this communication. JED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 25 J	<u>lune 2003</u> .					
2a) This action is FINAL . 2b) ☐ Th	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>31-38</u> is/are pending in the application	n.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>31-38</u> is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of Informa	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)				



Application/Control Number: 09/189,043

Art Unit: 1616

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/25/2003 has been entered.

Response to Amendment

The amendment filed 6/25/2003 has been entered. All the previously existing pending claims have been canceled. New claims 31-38 have been entered and are pending herein. **NOTE**: These new claims were presented in the amendment of 6/25/2003 as new claims 1-8, but have been renumbered 31-38 in accordance with 37 CFR 1.126.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 31-38 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The subject matter of claims 31-36 was not described in the specification. For example, the specification fails to describe the method of "collecting temporally spaced sets of 3-D and 2-D data, each data set collected serially throughout an acquisition or collection time; comparing 3-D and 2-D data from temporally spaced set of data by evaluating 2-D or 3-D temporally acquired images to assess the blood flow or angiographic abnormality or variation" as now recited in the claims. The specification also fails to describe any of the limitations set forth in claims 32-36 because there is no description of a physician to visually examine 3-D and 2-D data or software to quantitatively manipulate such data. Also, the time frames set forth in claims 34-35 have are not described. Also, in claim 36, such sequences are not described for the method as set



Application/Control Number: 09/189,043

Art Unit: 1616

forth in claim 31. While the disclosure describes spin echo and various imaging modalities, there is nothing to show that applicant envisioned a method wherein the collection, comparison and evaluation of 2-D and 3-D data is employed, as recited in the instant methods.

In claims 37 and 38, the recitation of "single shot imaging procedure" was not described in the specification. There is nothing in the specification which describes such an imaging modality, in fact, the specification describes taking a series of temporally spaced images, but not with a single shot.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 31-36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 31, the recitation of "comparing 3-D and 2-D data from temporally spaced set of data by evaluating 2-D or 3-D temporally acquired images to assess the blood flow or angiographic abnormality or variation" is confusing because it is unclear how comparing 3-D and 2-D data can be done by evaluating 2-D or 3-D data, since such comparing of 2-D and 3-D data would necessitate evaluating both 2-D and 3-D images. It is unclear if this "or" in the second to last line of claim 31 should be an "and" to clarify. This same situation is present in claim 33, which recites "2-D or 3-D" data.

The dependent claims fall therewith.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).



Application/Control Number: 09/189,043

Art Unit: 1616

Claims 37 and 38 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-6 and 15 of U.S. Patent No. 5,190,744. Although the conflicting claims are not identical, they are not patentably distinct from each other because the pending claims are encompassed by the patented claims, that is, the pending claims are drawn to a method which is anticipated by the patented claims. For example, the pending claims only differ as they recite specific imaging modalities that are employed, including fast imaging. Such fast imaging modalities are encompassed by the patented claims as shown by claim 15. Also, the instant claims are drawn to methods wherein the subjects are "humans" while the patented claims include both human and nonhuman subjects.

Specification

The specification fails to include a section under "Brief Description of the Drawings" as required to describe the figures filed with the application.

Conclusion

No claims are allowed at this time. However, the instant claims are free of the art of record. The prior art fails to teach or suggest method of detecting blood flow or angiographic abnormalities having the steps of imaging and acquiring, comparing and evaluating the 2-D and 3-D data as claimed in claim 31-36 or the methods of quantitatively evaluating blood flow abnormalities as set forth in claims 37-38.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael G. Hartley whose telephone number is (703) 308-4411. The examiner can normally be reached on M-F, 7:30-5, off alternative Mondays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

> Michael G. Hartley Primary Examiner

Art Unit 1616